

Karen Canfell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5479405/publications.pdf>

Version: 2024-02-01

254
papers

7,883
citations

57631

44
h-index

71532

76
g-index

259
all docs

259
docs citations

259
times ranked

7586
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	6
2	What would I do? Perspectives on the factors underlying Lynch syndrome genetic testing and results sharing decisions for high-risk colorectal cancer patients. <i>Psycho-Oncology</i> , 2022, 31, 587-596.	1.0	5
3	Thyroid cancers potentially preventable by reducing overweight and obesity in Australia: A pooled cohort study. <i>International Journal of Cancer</i> , 2022, 150, 1281-1290.	2.3	8
4	Socioeconomic disparities in colorectal cancer survival: contributions of prognostic factors in a large Australian cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2971-2984.	1.2	5
5	Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study. <i>Journal of Medical Screening</i> , 2022, 29, 72-83.	1.1	8
6	Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 588-594.	1.1	2
7	Reflections from field notes: An oral human papillomavirus infection and oropharyngeal cancer study among Indigenous Australians. <i>Australian Journal of Rural Health</i> , 2022, , .	0.7	0
8	Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. <i>Journal of Thoracic Oncology</i> , 2022, 17, 688-699.	0.5	24
9	The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study. <i>Journal of Cancer Policy</i> , 2022, 32, 100325.	0.6	6
10	National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study. <i>BMJ, The</i> , 2022, 376, e068582.	3.0	16
11	Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040. <i>Scientific Reports</i> , 2022, 12, 3994.	1.6	5
12	The IARC Perspective on Cervical Cancer Screening. <i>Obstetrical and Gynecological Survey</i> , 2022, 77, 154-156.	0.2	1
13	Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea. <i>BMJ Global Health</i> , 2022, 7, e007380.	2.0	13
14	Accurate categorisation of menopausal status for research studies: a step-by-step guide and detailed algorithm considering age, self-reported menopause and factors potentially masking the occurrence of menopause. <i>BMC Research Notes</i> , 2022, 15, 88.	0.6	5
15	Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods. <i>Lung Cancer</i> , 2022, 166, 122-131.	0.9	7
16	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies. <i>Journal of Cancer Policy</i> , 2022, 32, 100328.	0.6	6
17	Oral HPV Infection among Indigenous Australians; Incidence, Persistence, and Clearance at 12-Month Follow-up. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 604-613.	1.1	4
18	Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia. <i>Cancer Epidemiology</i> , 2022, 78, 102159.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Measuring school level attributable risk to support school-based HPV vaccination programs. BMC Public Health, 2022, 22, 822.	1.2	6
20	Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven Australian hospitals. Hereditary Cancer in Clinical Practice, 2022, 20, 18.	0.6	2
21	Health utilities for participants in a population-based sample who meet eligibility criteria for lung cancer screening. Lung Cancer, 2022, 169, 47-54.	0.9	3
22	Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2827-2840.	1.2	3
23	Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: a statistical modelling study. Lancet Public Health, The, 2022, 7, e537-e548.	4.7	38
24	Projections of smoking-related cancer mortality in Australia to 2044. Journal of Epidemiology and Community Health, 2022, 76, 792-799.	2.0	0
25	The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. Genetics in Medicine, 2022, 24, 1831-1846.	1.1	6
26	Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 532-539.	1.1	10
27	Selection of high-risk individuals for esophageal cancer screening: A prediction model of esophageal squamous cell carcinoma based on a multicenter screening cohort in rural China. International Journal of Cancer, 2021, 148, 329-339.	2.3	36
28	Is it possible to halve the incidence of liver cancer in China by 2050?. International Journal of Cancer, 2021, 148, 1051-1065.	2.3	85
29	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 268-277.	1.1	24
30	Health economic evaluation of primary human papillomavirus screening in urban populations in China. Cancer Epidemiology, 2021, 70, 101861.	0.8	5
31	Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 847-857.	0.7	3
32	Alcohol consumption, drinking patterns and cancer incidence in an Australian cohort of 226,162 participants aged 45 years and over. British Journal of Cancer, 2021, 124, 513-523.	2.9	26
33	Treatment abandonment in children with cancer: Does a sex difference exist? A systematic review and meta-analysis of evidence from low- and middle-income countries. International Journal of Cancer, 2021, 148, 895-904.	2.3	5
34	Large-scale systematic analysis of exposure to multiple cancer risk factors and the associations between exposure patterns and cancer incidence. Scientific Reports, 2021, 11, 2343.	1.6	2
35	Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiology, 2021, 70, 101874.	0.8	11
36	How Well Have Projected Lung Cancer Rates Predicted the Actual Observed Rates?. Asian Pacific Journal of Cancer Prevention, 2021, 22, 437-445.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Eliminating cervical cancer in the COVID-19 era. <i>Nature Cancer</i> , 2021, 2, 133-134.	5.7	18
38	Impact of Covid-19 Related Disruptions to Colorectal Cancer Screening Programs in Three Countries: A Comparative Modelling Study. , 2021, 53, .		0
39	Impact of COVID-19-related care disruptions on cervical cancer screening in the United States. <i>Journal of Medical Screening</i> , 2021, 28, 213-216.	1.1	34
40	Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic <sc>HIV</sc> infection and active <sc>HIV</sc> control. <i>International Journal of Cancer</i> , 2021, 149, 297-306.	2.3	5
41	Psychosocial impact of COVID-19 on cancer patients, survivors, and carers in Australia: a real-time assessment of cancer support services. <i>Supportive Care in Cancer</i> , 2021, 29, 5463-5473.	1.0	49
42	Poor self-rated oral health associated with poorer general health among Indigenous Australians. <i>BMC Public Health</i> , 2021, 21, 424.	1.2	3
43	Care to Quit: a stepped wedge cluster randomised controlled trial to implement best practice smoking cessation care in cancer centres. <i>Implementation Science</i> , 2021, 16, 23.	2.5	5
44	Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. <i>PLoS Medicine</i> , 2021, 18, e1003534.	3.9	30
45	Psychometric properties of the EQ-5D-5L for aboriginal Australians: a multi-method study. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 81.	1.0	11
46	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 304-314.	3.7	99
47	The Future Burden of Head and Neck Cancers Attributable to Modifiable Behaviors in Australia: A Pooled Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1566-1574.	1.1	2
48	Cancer incidence and cancer death in relation to tobacco smoking in a population-based Australian cohort study. <i>International Journal of Cancer</i> , 2021, 149, 1076-1088.	2.3	29
49	Birth-cohort estimates of smoking initiation and prevalence in 20th century Australia: Synthesis of data from 33 surveys and 385,810 participants. <i>PLoS ONE</i> , 2021, 16, e0250824.	1.1	3
50	Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?. <i>Tumour Virus Research</i> , 2021, 11, 200216.	1.5	8
51	Working towards a comprehensive understanding of HPV and cervical cancer among Indigenous women: a qualitative systematic review. <i>BMJ Open</i> , 2021, 11, e050113.	0.8	4
52	Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. <i>BMJ Open</i> , 2021, 11, e046928.	0.8	13
53	A systematic review and meta-analysis of the prevalence of human papillomavirus infection in Indigenous populations – A Global Picture. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 843-854.	1.4	7
54	Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians. <i>BMC Public Health</i> , 2021, 21, 1455.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Population-based utility scores for HPV infection and cervical squamous cell carcinoma among Australian Indigenous women. <i>PLoS ONE</i> , 2021, 16, e0254575.	1.1	1
56	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. <i>Clinical Oncology</i> , 2021, 33, 550-559.	0.6	32
57	Menopausal hormone therapy: Characterising users in an Australian national cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0253725.	1.1	2
58	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
59	The road to cervical cancer elimination in Malaysia: Evaluation of the impact and cost-effectiveness of human papillomavirus screening with self-collection and digital registry support. <i>International Journal of Cancer</i> , 2021, 149, 1997-2009.	2.3	11
60	656Risk factors for lung cancer in never-smokers in Australia. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
61	Self-collection for HPV screening: a game changer in the elimination of cervical cancer. <i>Medical Journal of Australia</i> , 2021, 215, 347-348.	0.8	6
62	The impact of HPV vaccination beyond cancer prevention: effect on pregnancy outcomes. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3562-3576.	1.4	5
63	965The estimated impact of improved breast screening tests targeted at women with dense breasts. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
64	863Alcohol and cancer in an Australian cohort of 226,162 participants aged 45 years and over. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
65	Cancer care disruption and reorganisation during the COVID-19 pandemic in Australia: A patient, carer and healthcare worker perspective. <i>PLoS ONE</i> , 2021, 16, e0257420.	1.1	52
66	Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an example: A modelled analysis. <i>Preventive Medicine</i> , 2021, 151, 106623.	1.6	34
67	Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states. <i>Vaccine</i> , 2021, 39, 6117-6126.	1.7	6
68	The impact of the Covid-19 pandemic on breast cancer early detection and screening. <i>Preventive Medicine</i> , 2021, 151, 106585.	1.6	68
69	OA19.01 Prospective Study of Lung Cancer Screening Criteria: USPSTF2013 vs PLCOm2012 " International Lung Screening Trial (ILST) Results. <i>Journal of Thoracic Oncology</i> , 2021, 16, S881.	0.5	0
70	School-Level Variation in Coverage of Co-Administered dTpa and HPV Dose 1 in Three Australian States. <i>Vaccines</i> , 2021, 9, 1202.	2.1	4
71	The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 1908-1918.	13.9	125
72	Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. <i>PLoS ONE</i> , 2021, 16, e0260088.	1.1	5

#	ARTICLE	IF	CITATIONS
73	The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. <i>International Journal of Cancer</i> , 2020, 146, 874-883.	2.3	15
74	The predicted impact and cost-effectiveness of systematic testing of people with incident colorectal cancer for Lynch syndrome. <i>Medical Journal of Australia</i> , 2020, 212, 72-81.	0.8	22
75	The Key Role of Mathematical Modeling and Health Economics in the Public Health Transitions in Cervical Cancer Prevention. , 2020, , 333-347.		0
76	Evaluating health benefits and cost-effectiveness of a mass-media campaign for improving participation in the National Bowel Cancer Screening Program in Australia. <i>Public Health</i> , 2020, 179, 90-99.	1.4	25
77	Estimating the Natural History of Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 955-963.	3.0	37
78	Trends in Prescribing Menopausal Hormone Therapy and Bisphosphonates in Australia and Manitoba, Canada and Adherence to Recommendations. <i>Journal of Women's Health</i> , 2020, 29, 177-186.	1.5	9
79	High-Risk Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma Among Non-Indigenous and Indigenous Populations: A Systematic Review. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 165, 019459982097504.	1.1	3
80	The Impact of Different Screening Model Structures on Cervical Cancer Incidence and Mortality Predictions: The Maximum Clinical Incidence Reduction (MCLIR) Methodology. <i>Medical Decision Making</i> , 2020, 40, 474-482.	1.2	5
81	Historical and projected hysterectomy rates in the USA: Implications for future observed cervical cancer rates and evaluating prevention interventions. <i>Gynecologic Oncology</i> , 2020, 158, 710-718.	0.6	16
82	Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in Australia. <i>BMJ Open</i> , 2020, 10, e036475.	0.8	1
83	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , 2020, 15, e0238018.	1.1	11
84	The health and economic impact of implementation strategies for improving detection of hereditary cancer patients' protocol for an in-depth cost-effectiveness evaluation with microsimulation modelling. <i>Implementation Science Communications</i> , 2020, 1, .	0.8	1
85	Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials. <i>Medical Decision Making</i> , 2020, 40, 815-829.	1.2	14
86	Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. <i>The Lancet Global Health</i> , 2020, 8, e1335-e1344.	2.9	86
87	Prevalence of Oral Human Papillomavirus Infection Among Australian Indigenous Adults. <i>JAMA Network Open</i> , 2020, 3, e204951.	2.8	26
88	Changes in cancer incidence and mortality in Australia over the period 1996-2015. <i>BMC Research Notes</i> , 2020, 13, 561.	0.6	6
89	The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort. <i>Australian and New Zealand Journal of Public Health</i> , 2020, 44, 219-226.	0.8	2
90	Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. <i>Journal of Infectious Diseases</i> , 2020, 222, 499-508.	1.9	17

#	ARTICLE	IF	CITATIONS
91	The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: A modelling study. PLoS ONE, 2020, 15, e0231388.	1.1	20
92	Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. British Journal of Cancer, 2020, 122, 1577-1579.	2.9	21
93	Protocol and Rationale for the International Lung Screening Trial. Annals of the American Thoracic Society, 2020, 17, 503-512.	1.5	56
94	Projected time to elimination of cervical cancer in the USA: a comparative modelling study. Lancet Public Health, The, 2020, 5, e213-e222.	4.7	59
95	Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health, The, 2020, 5, e223-e234.	4.7	141
96	Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment. PLoS ONE, 2020, 15, e0227899.	1.1	16
97	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 575-590.	6.3	421
98	Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 591-603.	6.3	321
99	How has COVID-19 impacted cancer screening? Adaptation of services and the future outlook in Australia. Public Health Research and Practice, 2020, 30, .	0.7	41
100	<scp>HPV</scp> swab selfâ€collection and cervical cancer in women who have sex with women. Medical Journal of Australia, 2020, 213, 239.	0.8	10
101	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. , 2020, 15, e0238018.		0
102	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. , 2020, 15, e0238018.		0
103	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. , 2020, 15, e0238018.		0
104	Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. , 2020, 15, e0238018.		0
105	Title is missing!. , 2020, 15, e0231388.		0
106	Title is missing!. , 2020, 15, e0231388.		0
107	Title is missing!. , 2020, 15, e0231388.		0
108	Title is missing!. , 2020, 15, e0231388.		0

#	ARTICLE	IF	CITATIONS
109	Spatial variation in cervical cancer screening participation and outcomes among Indigenous and non-Indigenous Australians in Queensland. <i>Geographical Research</i> , 2019, 57, 111-122.	0.9	4
110	Cancer costs and gender: a snapshot of issues, trends, and opportunities to reduce inequities using Australia as an example. <i>Climacteric</i> , 2019, 22, 538-543.	1.1	2
111	Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol. <i>Trials</i> , 2019, 20, 373.	0.7	10
112	Risk of childhood mortality associated with death of a mother in low-and-middle-income countries: a systematic review and meta-analysis. <i>BMC Public Health</i> , 2019, 19, 1281.	1.2	7
113	Identifying incident cancer cases in routinely collected hospital data: a retrospective validation study. <i>BMC Research Notes</i> , 2019, 12, 674.	0.6	1
114	Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e462-e472.	4.7	48
115	Statistical projection methods for lung cancer incidence and mortality: a systematic review. <i>BMJ Open</i> , 2019, 9, e028497.	0.8	21
116	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100184.	4.5	41
117	Development and application of a framework to estimate health care costs in China: The cervical cancer example. <i>PLoS ONE</i> , 2019, 14, e0222760.	1.1	5
118	Progress in eliminating HPV-associated disease. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100180.	4.5	0
119	Association of ten gastrointestinal and other medical conditions with positivity to faecal occult blood testing in routine screening: a large prospective study of women in England. <i>International Journal of Epidemiology</i> , 2019, 48, 549-558.	0.9	4
120	The burden of cervical cancer in Vietnam: Synthesis of the evidence. <i>Cancer Epidemiology</i> , 2019, 59, 83-103.	0.8	13
121	Towards the global elimination of cervical cancer. <i>Papillomavirus Research (Amsterdam,)</i> Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	4.5	122
122	Cancer elimination thresholds: one size does not fit all – Authors' reply. <i>Lancet Public Health</i> , The, 2019, 4, e87.	4.7	0
123	Towards global elimination of cervical cancer in all groups of women – Authors' reply. <i>Lancet Oncology</i> , The, 2019, 20, e239.	5.1	0
124	Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. <i>Climacteric</i> , 2019, 22, 596-602.	1.1	13
125	Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?. <i>Lung Cancer</i> , 2019, 130, 208-215.	0.9	16
126	The burden of pancreatic cancer in Australia attributable to smoking. <i>Medical Journal of Australia</i> , 2019, 210, 213-220.	0.8	6

#	ARTICLE	IF	CITATIONS
127	The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. <i>Gynecologic Oncology</i> , 2019, 152, 472-479.	0.6	7
128	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. <i>Gynecologic Oncology</i> , 2019, 152, 465-471.	0.6	14
129	The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study. <i>Gynecologic Oncology</i> , 2019, 153, 580-588.	0.6	10
130	The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study. <i>International Journal of Cancer</i> , 2019, 145, 2383-2394.	2.3	14
131	A Prospective Study of Health Conditions Related to Alcohol Consumption Cessation Among 97,852 Drinkers Aged 45 and Over in Australia. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 710-721.	1.4	43
132	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020â€™99: a modelling study. <i>Lancet Oncology</i> , The, 2019, 20, 394-407.	5.1	279
133	Impact of Scaled up Human Papillomavirus Vaccination and Cervical Screening and the Potential for Global Elimination of Cervical Cancer in 181 Countries, 2020â€™99: A Modelling Study. <i>Obstetrical and Gynecological Survey</i> , 2019, 74, 345-347.	0.2	1
134	Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 83-90.	1.1	81
135	A hepatitis B vaccine booster shot at age 10 could be cost-saving in China: But is it too soon to tell?. <i>International Journal of Infectious Diseases</i> , 2019, 78, 128-129.	1.5	1
136	Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	20
137	Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993â€™2016. <i>Journal of Medical Screening</i> , 2019, 26, 104-112.	1.1	0
138	The projected timeframe until cervical cancer elimination in Australia: a modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e19-e27.	4.7	268
139	Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. <i>Public Health Research and Practice</i> , 2019, 29, .	0.7	24
140	Prospects for cost-effective lung cancer screening using risk calculators. <i>Translational Cancer Research</i> , 2019, 8, S141-S144.	0.4	5
141	Evaluation of the benefits, harms and costâ€™effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. <i>International Journal of Cancer</i> , 2018, 143, 269-282.	2.3	28
142	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25â€™69 years living in Australia. <i>BMJ Open</i> , 2018, 8, e016700.	0.8	20
143	Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1094-1105.	0.5	29
144	Cervical screening in HPV-vaccinated populations. <i>Climacteric</i> , 2018, 21, 227-234.	1.1	8

#	ARTICLE	IF	CITATIONS
145	Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. <i>Scientific Reports</i> , 2018, 8, 4261.	1.6	12
146	Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort. <i>Preventive Medicine</i> , 2018, 106, 185-193.	1.6	29
147	Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. <i>PLoS ONE</i> , 2018, 13, e0205034.	1.1	7
148	The Future Colorectal Cancer Burden Attributable to Modifiable Behaviors: A Pooled Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky033.	1.4	9
149	Inaccurate and fundamentally flawed analysis risks undermining confidence in cervical screening programs. <i>Journal of the American Society of Cytopathology</i> , 2018, 7, 336-338.	0.2	1
150	Anal cancer in high-income countries: Increasing burden of disease. <i>PLoS ONE</i> , 2018, 13, e0205105.	1.1	71
151	Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012). <i>PLoS ONE</i> , 2018, 13, e0196764.	1.1	16
152	Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1450-1461.	1.1	26
153	Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. <i>Vaccine</i> , 2018, 36, 6314-6324.	1.7	6
154	Lung cancer mortality in Australia: Projected outcomes to 2040. <i>Lung Cancer</i> , 2018, 125, 68-76.	0.9	21
155	Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. <i>PLoS ONE</i> , 2018, 13, e0201552.	1.1	70
156	Patterns of care and emergency presentations for people with non-small cell lung cancer in New South Wales, Australia: A population-based study. <i>Lung Cancer</i> , 2018, 122, 171-179.	0.9	16
157	Hormonal contraceptive use and smoking as risk factors for high-grade cervical intraepithelial neoplasia in unvaccinated women aged 30-44 years: A case-control study in New South Wales, Australia. <i>Cancer Epidemiology</i> , 2018, 55, 162-169.	0.8	16
158	The future burden of lung cancer attributable to current modifiable behaviours: a pooled study of seven Australian cohorts. <i>International Journal of Epidemiology</i> , 2018, 47, 1772-1783.	0.9	9
159	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia. <i>PLoS ONE</i> , 2018, 13, e0185332.	1.1	52
160	Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. <i>JMIR Research Protocols</i> , 2018, 7, e10503.	0.5	17
161	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. <i>Lancet Public Health</i> , The, 2017, 2, e96-e107.	4.7	124
162	Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO ₂₀₁₂ risk prediction tool. <i>International Journal of Cancer</i> , 2017, 141, 242-253.	2.3	73

#	ARTICLE	IF	CITATIONS
163	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. <i>International Journal of Cancer</i> , 2017, 140, 2192-2200.	2.3	83
164	Impact of the National Cervical Screening Programme in New Zealand by age: analysis of cervical cancer trends 1985â€“2013 in all women and in Mori women. <i>Cancer Causes and Control</i> , 2017, 28, 1393-1404.	0.8	18
165	Cost-effectiveness estimates: the need for complete reporting â€“ Authors' reply. <i>Lancet Public Health</i> , The, 2017, 2, e212.	4.7	2
166	Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 134-141.	4.5	15
167	Vulvar cancer in highâ€“income countries: Increasing burden of disease. <i>International Journal of Cancer</i> , 2017, 141, 2174-2186.	2.3	75
168	A new era for cervical screening in Australia: Watch this space!. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2017, 57, 499-501.	0.4	9
169	How will transitioning from cytology to <scp>HPV</scp> testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in <scp>A</scp>ustralia, a high vaccination coverage country. <i>International Journal of Cancer</i> , 2017, 141, 2410-2422.	2.3	25
170	Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. <i>Lancet Public Health</i> , The, 2017, 2, e331-e340.	4.7	114
171	Identifying incident colorectal and lung cancer cases in health service utilisation databases in Australia: a validation study. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 23.	1.5	29
172	Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations. <i>BMC Health Services Research</i> , 2017, 17, 326.	0.9	8
173	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. <i>PLoS Medicine</i> , 2017, 14, e1002388.	3.9	67
174	Time to clinical investigation for Indigenous and nonâ€“Indigenous Queensland women after a high grade abnormal Pap smear, 2000â€“2009. <i>Medical Journal of Australia</i> , 2017, 206, 73-77.	0.8	11
175	The burden of cancer attributable to modifiable risk factors: the Australian cancer-PAF cohort consortium. <i>BMJ Open</i> , 2017, 7, e016178.	0.8	22
176	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. <i>PLoS ONE</i> , 2017, 12, e0163509.	1.1	26
177	Impact of HPV sample selfâ€“collection for underscreened women in the renewed Cervical Screening Program. <i>Medical Journal of Australia</i> , 2016, 204, 194-194.	0.8	35
178	Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000â€“2011. <i>PLoS ONE</i> , 2016, 11, e0150473.	1.1	9
179	Impact of the Australian National Cervical Screening Program in women of different ages. <i>Medical Journal of Australia</i> , 2016, 205, 359-364.	0.8	47
180	Using probabilistic record linkage methods to identify Australian Indigenous women on the Queensland Pap Smear Register: the National Indigenous Cervical Screening Project. <i>BMJ Open</i> , 2016, 6, e009540.	0.8	12

#	ARTICLE	IF	CITATIONS
181	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health, The</i> , 2016, 1, e8-e17.	4.7	210
182	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. <i>Lancet Public Health, The</i> , 2016, 1, e66-e75.	4.7	37
183	Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. <i>International Journal of Cancer</i> , 2016, 139, 2771-2780.	2.3	62
184	Past cervical intraepithelial neoplasia grade 3, obesity, and earlier menopause are associated with an increased risk of vulval cancer in postmenopausal women. <i>British Journal of Cancer</i> , 2016, 115, 599-606.	2.9	22
185	The molecular characteristics of colonic neoplasms in serrated polyposis: a systematic review and meta-analysis. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 127-137.	1.3	15
186	The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011). <i>Cancer</i> , 2016, 122, 1560-1569.	2.0	46
187	Resilience of a FIT screening programme against screening fatigue: a modelling study. <i>BMC Public Health</i> , 2016, 16, 1009.	1.2	8
188	Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. <i>BMC Health Services Research</i> , 2016, 16, 147.	0.9	36
189	Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Whites Cancer, Lifestyle and Evaluation of Risk study. <i>International Journal of Cancer</i> , 2016, 138, 1905-1914.	2.3	8
190	Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality—Model-Based Exploration of the Serrated Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 135-144.	1.1	25
191	Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0146494.	1.1	28
192	Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. <i>PLoS ONE</i> , 2016, 11, e0151619.	1.1	49
193	Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. <i>BMC Infectious Diseases</i> , 2015, 16, 52.	1.3	19
194	Effect of changes in treatment practice on survival for cervical cancer: results from a population-based study in Manitoba, Canada. <i>BMC Cancer</i> , 2015, 15, 642.	1.1	9
195	Who should be vaccinated against HPV?. <i>BMJ, The</i> , 2015, 350, h2244-h2244.	3.0	7
196	Changing Trends in Vulvar Cancer Incidence and Mortality Rates in Australia Since 1982. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1683-1689.	1.2	43
197	The Cancer, Lifestyle and Evaluation of Risk Study (CLEAR): Rationale and design of an unmatched case-spouse control study of over 10,000 participants in New South Wales, Australia. <i>Cancer Epidemiology</i> , 2015, 39, 414-423.	0.8	6
198	Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. <i>BMC Infectious Diseases</i> , 2015, 15, 365.	1.3	3

#	ARTICLE	IF	CITATIONS
199	HPV vaccination and pregnancy. <i>BMJ, The</i> , 2015, 351, h4705.	3.0	8
200	Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. <i>Cancer Epidemiology</i> , 2015, 39, 600-611.	0.8	13
201	Factors related to vaccine uptake by young adult women in the catch-up phase of the National HPV Vaccination Program in Australia: Results from an observational study. <i>Vaccine</i> , 2015, 33, 2387-2394.	1.7	25
202	Fall in Genital Warts Diagnoses in the General and Indigenous Australian Population Following Implementation of a National Human Papillomavirus Vaccination Program: Analysis of Routinely Collected National Hospital Data. <i>Journal of Infectious Diseases</i> , 2015, 211, 91-99.	1.9	71
203	Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. <i>Vaccine</i> , 2015, 33, 34-51.	1.7	9
204	Modeling the Adenoma and Serrated Pathway to Colorectal Cancer (ASCCA). <i>Risk Analysis</i> , 2014, 34, 889-910.	1.5	35
205	High-grade cervical abnormalities and cervical cancer in women following a negative Pap smear with and without an endocervical component: A cohort study with 10 years of follow-up. <i>International Journal of Cancer</i> , 2014, 135, 1213-1219.	2.3	6
206	A survey of population-based utility scores for cervical cancer prevention. <i>BMC Research Notes</i> , 2014, 7, 899.	0.6	13
207	Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study. <i>BMC Infectious Diseases</i> , 2014, 14, 3861.	1.3	8
208	Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway. <i>Value in Health</i> , 2014, 17, A323.	0.1	1
209	Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. <i>BMC Infectious Diseases</i> , 2014, 14, 351.	1.3	30
210	Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. <i>BMC Research Notes</i> , 2014, 7, 109.	0.6	14
211	Incremental Benefits of Male HPV Vaccination: Accounting for Inequality in Population Uptake. <i>PLoS ONE</i> , 2014, 9, e101048.	1.1	15
212	The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. <i>Health Technology Assessment</i> , 2014, 18, 1-196.	1.3	112
213	Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. <i>BMC Infectious Diseases</i> , 2013, 13, 114.	1.3	19
214	Cancer incidence and mortality in people aged less than 75 years: Changes in Australia over the period 1987-2007. <i>Cancer Epidemiology</i> , 2013, 37, 780-787.	0.8	20
215	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, I1-I31.	1.7	261
216	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. <i>Vaccine</i> , 2013, 31, H1-H31.	1.7	272

#	ARTICLE	IF	CITATIONS
217	Uptake of liquid-based cytology as an adjunct to conventional cytology for cervical screening in NSW, Australia: a cross-sectional and population-based cohort analysis. BMC Public Health, 2013, 13, 1196.	1.2	1
218	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
219	Quantifying the impact of dissimilar HPV vaccination uptake among Manitoban school girls by ethnicity using a transmission dynamic model. Vaccine, 2013, 31, 4848-4855.	1.7	12
220	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33
221	The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England. Cancer Causes and Control, 2013, 24, 1727-1736.	0.8	25
222	Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Caseâ€“Control Study. PLoS Medicine, 2012, 9, e1001182.	3.9	85
223	Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ, The, 2012, 345, e7086-e7086.	3.0	35
224	Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Services Research, 2012, 12, 123.	0.9	34
225	Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research, 2012, 12, 446.	0.9	18
226	Cervical cancer screening in Middle Eastern and Asian migrants to Australia: A record linkage study. Cancer Epidemiology, 2012, 36, e394-e400.	0.8	96
227	Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries. Vaccine, 2012, 30, F157-F167.	1.7	97
228	Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia. BMC Cancer, 2012, 12, 491.	1.1	13
229	A revision of sexual mixing matrices in models of sexually transmitted infection. Statistics in Medicine, 2012, 31, 3419-3432.	0.8	9
230	The burden of cervical cancer in China: Synthesis of the evidence. International Journal of Cancer, 2012, 130, 641-652.	2.3	127
231	Participation in cervical screening by older asian and middle eastern migrants in new South wales, australia. Health Promotion Perspectives, 2012, 2, 274-86.	0.8	4
232	Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine, 2011, 29, 2487-2494.	1.7	69
233	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 2011, 29, 9112-9122.	1.7	58
234	An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Review of Endocrinology and Metabolism, 2011, 6, 397-409.	1.2	8

#	ARTICLE	IF	CITATIONS
235	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. <i>BMC Cancer</i> , 2011, 11, 239.	1.1	51
236	Models of cervical screening in the era of human papillomavirus vaccination. <i>Sexual Health</i> , 2010, 7, 359.	0.4	8
237	Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. <i>BMC Public Health</i> , 2010, 10, 734.	1.2	35
238	Monitoring HPV vaccination programmes. <i>BMJ: British Medical Journal</i> , 2010, 340, c1666-c1666.	2.4	7
239	Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible. <i>Breast Cancer Research</i> , 2010, 12, 103.	2.2	14
240	Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. <i>Medical Journal of Australia</i> , 2009, 190, 164-165.	0.8	1
241	Invited Commentary: Hormone Therapy Risks and Benefits–The Women's Health Initiative Findings and the Postmenopausal Estrogen Timing Hypothesis. <i>American Journal of Epidemiology</i> , 2009, 170, 24-28.	1.6	59
242	Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 671-673.	1.1	29
243	Oral Contraceptives, Hormone Replacement Therapy, and Cancers of the Female Reproductive System. , 2009, , 111-130.		0
244	The predicted impact of vaccination on human papillomavirus infections in Australia. <i>International Journal of Cancer</i> , 2008, 123, 1854-1863.	2.3	48
245	Normal endometrial cells in cervical cytology: systematic review of prevalence and relation to significant endometrial pathology. <i>Journal of Medical Screening</i> , 2008, 15, 188-198.	1.1	9
246	HRT and Breast Cancer: Recent Findings in the Context of the Evidence to Date. <i>Women's Health</i> , 2008, 4, 427-431.	0.7	6
247	Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. <i>Medical Journal of Australia</i> , 2008, 188, 641-644.	0.8	117
248	Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. <i>Medical Journal of Australia</i> , 2006, 185, 482-486.	0.8	97
249	The agreement between self-reported cervical smear abnormalities and screening programme records. <i>Journal of Medical Screening</i> , 2006, 13, 72-75.	1.1	11
250	Factors predicting successful DNA recovery from archival cervical smear samples. <i>Cytopathology</i> , 2004, 15, 276-282.	0.4	13
251	The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. <i>British Journal of Cancer</i> , 2004, 91, 530-536.	2.9	81
252	A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: A multicenter evaluation. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 804-811.	1.2	35

#	ARTICLE	IF	CITATIONS
253	Real-Time Devices for the Screening and Diagnosis of Cervical Neoplasia. , 0, , 387-398.		1
254	HPV screening for cervical cancer is reaching maturity. BMJ, The, 0, , o1303.	3.0	3